Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi:10.3322/caac.21332.
   PubMed Web of Science ®Google Scholar
• Bright R, Coventry BJ, Eardley-Harris N, Briggs N. Clinical response rates from interleukin-2 therapy for metastatic melanoma over 30 years' experience: a meta-analysis of 3312 patients. J Immunother. 2017;40:21–30. doi:10.1097/CJI.0000000000000149. PMID:27875387
   PubMed Web of Science ®Google Scholar
• Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Can J Sci Am. 2000;6 Suppl 1:S11–4.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–16. doi:10.1200/JCO.1999.17.7.2105. PMID:10561265
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New England J Med. 2010;363:711–23. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30. doi:10.1200/JCO.2013.53.0105. PMID:24590637
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–44. doi:10.1056/NEJMoa1305133. PMID:23724846
   PubMed Web of Science ®Google Scholar
• Koller KM, Wang W, Schell TD, Cozza EM, Kokolus KM, Neves RI, Mackley HB, Pameijer C, Leung A, Anderson B, et al. Malignant melanoma-The cradle of anti-neoplastic immunotherapy. Crit Rev Oncol Hematol. 2016;106:25–54. doi:10.1016/j.critrevonc.2016.04.010. PMID:27637351
   PubMed Web of Science ®Google Scholar
• Hughes T, Klairmont M, Sharfman WH, Kaufman HL. Interleukin-2, ipilimumab, and anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma. Cancer Biol Ther. 2015. doi:10.1080/15384047.2015.1095401. [Epub ahead of print]
   PubMedGoogle Scholar
• Kin NW, Sanders VM. It takes nerve to tell T and B cells what to do. J Leukoc Biol. 2006;79:1093–104. doi:10.1189/jlb.1105625. PMID:16531560
   PubMed Web of Science ®Google Scholar
• Bonneau RH, Kiecolt-Glaser JK, Glaser R. Stress-induced modulation of the immune response. Ann N Y Acad Sci. 1990;594:253–69. doi:10.1111/j.1749-6632.1990.tb40485.x. PMID:2165759
   PubMed Web of Science ®Google Scholar
• Kokolus KM, Capitano ML, Lee CT, Eng JW, Waight JD, Hylander BL, Sexton S, Hong CC, Gordon CJ, Abrams SI, et al. Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. Proc Natl Acad Sci U S A. 2013;110:20176–81. doi:10.1073/pnas.1304291110. PMID:24248371
   PubMed Web of Science ®Google Scholar
• Kokolus KM, Spangler HM, Povinelli BJ, Farren MR, Lee KP, Repasky EA. Stressful presentations:mild cold stress in laboratory mice influences phenotype of dendritic cells in naïve and tumor-bearing mice. Front Immunol. 2014;5:23. doi:10.3389/fimmu.2014.00023. PMID:24575090
   PubMed Web of Science ®Google Scholar
• Eng JWL, Reed CB, Kokolus KM, Pitoniak R, Utley A, Bucsek MJ, Ma WW, Repasky EA, Hylander BL, et al. Housing temperature-induced stress drives therapeutic resistance in murine tumor models through β2-adrenergic receptor activation. Nat Commun. 2015;10:6426. doi:10.1038/ncomms7426.
   Google Scholar
• Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, Montero MP, Serdjebi C, Kavallaris M, André N, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2:797–809. doi:10.18632/oncotarget.343. PMID:22006582
   PubMed Web of Science ®Google Scholar
• Slota C, Shi A, Chen G, Bevans M, Weng NP. Norepinephrine preferentially modulates memory CD8 T cell function inducing inflammatory cytokine production and reducing proliferation in response to activation. Brain Behav Immun. 2015;46:168–79. doi:10.1016/j.bbi.2015.01.015. PMID:25653192
   PubMed Web of Science ®Google Scholar
• Hoes AW. beta blockers for heart failure. Bmj. 2016;353:i2074. doi:10.1136/bmj.i2074. PMID:27099266
   PubMedGoogle Scholar
• Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810–52. doi:10.1161/CIR.0b013e31829e8807. PMID:23741057
   PubMed Web of Science ®Google Scholar
• DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D'Ascenzo F, Cerrato E, Biondi-Zoccai G, Lavie CJ, Bell DS, O'Keefe JH, et al. beta-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open heart. 2015;2:e000230. doi:10.1136/openhrt-2014-000230. PMID:25821584
   PubMed Web of Science ®Google Scholar
• Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F.. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1:628–38. doi:10.18632/oncotarget.197. PMID:21317458
   PubMed Web of Science ®Google Scholar
• Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 2011;29:2635–44. doi:10.1200/JCO.2010.33.5422. PMID:21632503
   PubMed Web of Science ®Google Scholar
• Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 2011;129:549–56. doi:10.1007/s10549-011-1505-3. PMID:21479924
   PubMed Web of Science ®Google Scholar
• Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29:2645–52. doi:10.1200/JCO.2010.33.4441. PMID:21632501
   PubMed Web of Science ®Google Scholar
• Botteri E, Munzone E, Rotmensz N, Cipolla C, De Giorgi V, Santillo, B, Zanelotti A, Adamoli L, Colleoni M, Viale G, et al. Therapeutic effect of beta-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat. 2013;140:567–75. doi:10.1007/s10549-013-2654-3. PMID:23912960
   PubMed Web of Science ®Google Scholar
• Diaz ES, Karlan BY, Li AJ. Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol. 2012;127:375–8. doi:10.1016/j.ygyno.2012.07.102. PMID:22819786
   PubMed Web of Science ®Google Scholar
• Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, et al. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 2015;121:3444–51. doi:10.1002/cncr.29392. PMID:26301456
   PubMed Web of Science ®Google Scholar
• Leigh ND, Kokolus KM, O'Neill RE, Du W, Eng JW, Qiu J, Chen GL, McCarthy PL, Farrar JD, Cao X, et al. Housing temperature-induced stress is suppressing murine graft-versus-host disease through beta2-adrenergic receptor signaling. J Immunol. 2015;195:5045–54. doi:10.4049/jimmunol.1500700. PMID:26459348
   PubMed Web of Science ®Google Scholar
• Estrada LD, Agac D, Farrar JD. Sympathetic neural signaling via the beta2-adrenergic receptor suppresses T-cell receptor-mediated human and mouse CD8(+) T-cell effector function. Eur J Immunol. 2016;46:1948–58. doi:10.1002/eji.201646395. PMID:27222010
   PubMed Web of Science ®Google Scholar
• Kuzu OF, Nguyen FD, Noory MA, Sharma A. Current state of animal (mouse) modeling in melanoma research. Cancer Growth Metastasis. 2015;8:81–94. PMID:26483610
   PubMedGoogle Scholar
• Fidler IJ, Bucana C. Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes. Cancer Res. 1977;37:3945–56. PMID:908034
   PubMed Web of Science ®Google Scholar
• Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell. 2015;162:1242–56. doi:10.1016/j.cell.2015.08.052. PMID:26359984
   PubMed Web of Science ®Google Scholar
• Chen S, Lee LF, Fisher TS, Jessen B, Elliott M, Evering W, Logronio K, Tu GH, Tsaparikos K, Li X, et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol Res. 2015;3:149–60. doi:10.1158/2326-6066.CIR-14-0118. PMID:25387892
   PubMed Web of Science ®Google Scholar
• Harry JD, Norris SC, Percival GC, Young J. The dose in humans at which ICI 118,551 (a selective beta 2-adrenoceptor blocking agent) demonstrates blockade of beta 1-adrenoceptors. Clin Pharmacol Ther. 1988;43:492–8. doi:10.1038/clpt.1988.64. PMID:2896555
   PubMed Web of Science ®Google Scholar
• Maisel AS, Fowler P, Rearden A, Motulsky HJ, Michel MC. A new method for isolation of human lymphocyte subsets reveals differential regulation of beta-adrenergic receptors by terbutaline treatment. Clin Pharmacol Ther. 1989;46:429–39. doi:10.1038/clpt.1989.161. PMID:2551559
   PubMed Web of Science ®Google Scholar
• Grailer JJ, Haggadone MD, Sarma JV, Zetoune FS, Ward PA. Induction of M2 regulatory macrophages through the beta2-adrenergic receptor with protection during endotoxemia and acute lung injury. J innate immun. 2014;6:607–18. doi:10.1159/000358524. PMID:24642449
   PubMed Web of Science ®Google Scholar
• Kizaki T, Shirato K, Sakurai T, Ogasawara JE, Oh-ishi S, Matsuoka T, Izawa T, Imaizumi K, Haga S, Ohno H. Beta2-adrenergic receptor regulate Toll-like receptor 4-induced late-phase NF-kappaB activation. Mol Immunol. 2009;46:1195–203. doi:10.1016/j.molimm.2008.11.005. PMID:19167076
   PubMed Web of Science ®Google Scholar
• Sanders VM, Baker RA, Ramer-Quinn DS, Kasprowicz DJ, Fuchs BA, Street NE. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J Immunol. 1997;158:4200–10. PMID:9126981
   PubMed Web of Science ®Google Scholar
• Guereschi MG, Araujo LP, Maricato JT, Takenaka MC, Nascimento VM, Vivanco BC, Reis VO, Keller AC, Brum PC, Basso AS. Beta2-adrenergic receptor signaling in CD4+ Foxp3+ regulatory T cells enhances their suppressive function in a PKA-dependent manner. Eur J Immunol. 2013;43:1001–12. doi:10.1002/eji.201243005. PMID:23436577
   PubMed Web of Science ®Google Scholar
• Grebe KM, Takeda K, Hickman HD, Bailey AL, Embry AC, Bennink JR, Yewdell JW. Cutting edge: Sympathetic nervous system increases proinflammatory cytokines and exacerbates influenza A virus pathogenesis. J Immunol. 2010;184:540–4. doi:10.4049/jimmunol.0903395. PMID:20018617
   PubMed Web of Science ®Google Scholar
• Kalinichenko VV, Mokyr MB, Graf LH, Jr., Cohen RL, Chambers DA. Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression. J Immunol. 1999;163:2492–9. PMID:10452985
   PubMed Web of Science ®Google Scholar
• Zalli A, Bosch JA, Goodyear O, Riddell N, McGettrick HM, Moss P, Wallace GR. Targeting β2 adrenergic receptors regulate human T cell function directly and indirectly. Brain Behav Immun. 2015;45:211–8. doi:10.1016/j.bbi.2014.12.001. PMID:25526818
   PubMed Web of Science ®Google Scholar
• M. Tsuji, T. Kuno, C. Tanaka, M. Ichihashi, Y. Mishima. Beta-adrenergic receptors of B16 melanoma cell. Arc Dermatol Res. 1983;275:415–416. doi:10.1007/BF00417345.
   PubMed Web of Science ®Google Scholar
• Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC, Webster Marketon JI, Barsky SH, Glaser R. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun. 2009;23:267–75. doi:10.1016/j.bbi.2008.10.005. PMID:18996182
   PubMed Web of Science ®Google Scholar
• Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B, Liu H, Kokolus KM, Eng JW, Messmer MN, et al. beta-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8+ T cells and undermines checkpoint inhibitor therapy. Cancer Res. 2017;77:5639–51. doi:10.1158/0008-5472.CAN-17-0546. PMID:28819022
   PubMed Web of Science ®Google Scholar
• Nakai A, Hayano Y, Furuta F, Noda M, Suzuki K. Control of lymphocyte egress from lymph nodes through beta2-adrenergic receptors. J Exp Med. 2014;211:2583–98. doi:10.1084/jem.20141132. PMID:25422496
   PubMed Web of Science ®Google Scholar